At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 221 enrolled
Drug / intervention
CC-93538 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating CC-93538 and Placebo for Dermatitis, Atopic and Eczema. Completed, enrolled 221 participants across 157 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic, Eczema
CountriesCanada, China, Czechia, Japan, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMay 2021
Primary CompletionJul 2022
Study CompletionNov 2022
TodayJul 2026
First PostedMar 16, 2021
Enrollment StartMay 14, 2021
Primary CompletionJul 20, 2022
Study CompletionNov 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.3 years ago
Interventions
CC-93538drug
Specified dosages on specified days
Placeboother
Specified dosages on specified days